West Pharm Svcs Stock Price, News & Analysis

Pneuma Systems Corporation has partnered with West Pharmaceutical Services (NYSE: WST) to enhance drug therapy patient experiences. This collaboration aims to develop drug delivery solutions utilizing Pneuma's innovative closed-loop fluid flow control platform, with West providing technical and financial support. The intravenous pump market, projected to reach USD 20.5 billion in five years, underscores the significance of this partnership. The collaboration emphasizes improvements in workflow and patient safety, as West integrates PneumaDrive™ technology into various healthcare settings.

West Pharmaceutical Services, Inc. (NYSE: WST) announced that its team members received prestigious awards at the 2022 PDA Annual Meeting in Dallas. Liang Fang and Marissa Rase were honored with the 2021 Fred Simon Award for their paper on excipient-container interactions affecting prefilled syringes. Additionally, Chief Scientific Officer Fran DeGrazio received the 2021 Edward Smith Packaging Science Award for significant contributions to pharmaceutical packaging. West continues to highlight its commitment to innovation and safety in injectable drug administration.

West Pharmaceutical Services (NYSE: WST) will participate in the 2022 PDA Annual Meeting in Exton, Pennsylvania, on April 4-6, 2022. The company plans to showcase advancements in packaging science through keynote presentations, moderated sessions, and scientific posters.

Key highlights include a presentation on a Closed-Loop Wearable Injector System for Naloxone and various poster sessions focusing on vial container closure systems and prefilled syringes. With $2.83 billion in net sales for 2021, West emphasizes its leadership in ensuring quality and stability in injectable drug products.

TYME Technologies, Inc. announces key leadership changes, appointing Christine D. Baker to its Board of Directors. With over 30 years in biotech, her expertise in business development and commercialization will guide the company's cancer therapies. Douglas A. Michels becomes Chairman of the Board, bringing 39 years of healthcare experience. The changes aim to strengthen TYME's position in developing cancer metabolism-based therapies (CMBTs™) and enhance its strategic direction.

West Pharmaceutical Services (NYSE: WST) has announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 23, 2022, at 9:00 a.m. EDT. The virtual event will feature a live audio webcast available in the 'Investors' section of its website. West specializes in high-quality injectable drug administration solutions, generating $2.83 billion in net sales in fiscal year 2021, with a workforce of approximately 10,000 across 50 sites worldwide.

West Pharmaceutical Services (NYSE: WST) has announced that Eric M. Green, the current President and CEO, will also serve as Chair of the Board starting May 24, 2022. He succeeds Patrick Zenner, who is retiring after 20 years. The company highlights Green's successful leadership during the pandemic and his focus on innovative, high-quality products. Additionally, Paolo Pucci has been appointed as the Lead Independent Director of the Board. West generated $2.83 billion in net sales in FY 2021 and employs about 10,000 team members globally.

West Pharmaceutical Services, Inc. (NYSE: WST) has declared a second-quarter 2022 dividend of $0.18 per share, payable on May 4, 2022, to shareholders on record as of April 20, 2022. The company, a leader in innovative injectable solutions, reported $2.83 billion in net sales for fiscal year 2021 and employs approximately 10,000 people across 50 sites globally. West continues to support the effective delivery of life-saving medicines, enhancing shareholder value through consistent dividends.

West Pharmaceutical Services reported its fourth-quarter and full-year 2021 financial results, showcasing significant growth. Q4 net sales reached $730.8 million, a 26% increase, with organic growth at 28.3%. Full-year sales totaled $2.832 billion, up 31.9%. Reported diluted EPS for Q4 was $1.93, a 49.6% rise, and $8.67 for the year, up 89.7%. The company projects 2022 net sales between $3.050 billion and $3.075 billion, with diluted EPS expected between $9.20 and $9.35. They noted strong demand in their Proprietary Products segment and plans for future growth.

West Pharmaceutical Services, a leader in injectable drug administration, will announce its fourth-quarter and full-year 2021 financial results on February 17, 2022, before the market opens. A conference call to discuss these results is scheduled for 9:00 a.m. ET on the same day. Participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International), using conference ID 1986145. An archive of the call will be available for review until February 24, 2022. For more information, visit www.westpharma.com.